Treatment Horizons

NAPWA helps to promote immune-based therapies by Chael Needle At the International AIDS Conference last June, the AIDS Institute and the National Association of People with AIDS...

Protecting One's Heart The REPRIEVE study aims to prevent cardiovascular disease by Chael Needle As people are living longer with HIV, researchers have been increasingly attending to...

LifeGuide A community perspective on PrEP delves into its pros & cons by Jeannie Gibbs Post-exposure prophylaxis (PrEP) is the provision of antiretrovirals (ARVs) to HIV-negative...

Chronic inflammation means the immune system is imbalanced—a natural immune response has persisted, or immune regulation is not working properly. Research has shown that...

Without the Pill Box? The First Long-Acting Injectable Regimen for Individuals Living with HIV Comes of Age by Mel Baker A funny thing happened on the way to...

In February 2018, ViiV Healthcare announced the start of a forty-eight-week phase III study designed to determine whether adults with HIV-1 who have achieved...

A treatment for advanced HIV-associated Kaposi’s sarcoma is relaunched by Chael Needle Newly acquired by Galen from Gilead Sciences, DaunoXome (daunorubicin citrate liposome injection) is an...

LifeGuide Dr. C. Everett Koop Revisits a Time When Neither Treatment nor Testing Existed by Chael Needle Knowing he had to face the micromanaging tendencies and...

Close to the Edit A functional cure candidate modifies genes to create HIV-resistant cells by Chael Needle Gary Blick, MD, AAHIVS, Medical & Research Director of CIRCLE...

A newly approved anti-diarrheal agent seeks to counter side effects of HAART by Chael Needle Recently, the FDA approved Fulyzaq (crofelemer) 125 mg delayed-release tablets for...